Oxidative Stress in Hemodialysis Patients: Pathophysiological Mechanisms, Clinical Consequences and Basic Principles of Treatment

1. Cozzolino M, Mangano M, Stucchi A, et al. (2018). Cardiovascular disease in dialysis patients. Nephrol Dial Transplant. 33(1), 28-34. DOI: 10.1093/ndt/gfy174.10.1093/ndt/gfy174616881630281132Search in Google Scholar

2. Zoccali C, Mallamaci F, Tripepi G. (2004). Novel Cardiovascular Risk Factors in End-Stage Renal Disease. J Am Soc Nephrol. 15(Suppl 1), 77-80. DOI: 10.1097/01.ASN.0000093240.84097.FE.10.1097/01.ASN.0000093240.84097.FESearch in Google Scholar

3. Locatelli F, Canaud B, Eckardt K-U, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272-80. DOI: 10.1093/ndt/gfg074.10.1093/ndt/gfg07412808161Search in Google Scholar

4. Descamps-Latscha B, Drüeke T, Witko-Sarsat V. (2001). Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 14(3), 793-9. DOI: 10.1046/j.1525-139X.2001.00052.x.10.1046/j.1525-139X.2001.00052.x11422926Search in Google Scholar

5. Liakopoulos V, Roumeliotis S, Gorny X, et al. (2017). Oxidative Stress in Hemodialysis Patients: A Review of the Literature. Oxidative Med Cell Long. 2017: 3081856., DOI: 10.1155/2017/3081856.10.1155/2017/3081856561337429138677Search in Google Scholar

6. Santoro A, Guadagni G. (2010). Dialysis membrane: from convection to adsorption. Nephrol Dial Transplant. 3(Suppl 1), 36-9. DOI: 10.1093/ndtplus/sfg035.10.1093/ndtplus/sfq035Search in Google Scholar

7. Ronco C, Clark W. Hemodialysis membranes. (2018). Nat Rev Nephrol. 14(6), 394-410. DOI: 10.1038/s41581-018-0002-x.10.1038/s41581-018-0002-x29730670Search in Google Scholar

8. Wu CC, Chen JS, Wu WM, et al. (2005). Myeloperoxidase serves as a marker of oxidative stress during single hemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant. 20(6), 1134-9. DOI: 10.1093/ndt/gfh764.10.1093/ndt/gfh76415814542Search in Google Scholar

9. Ward RA. Ultrapure Dialysate. (2004). Semin Dial. 17(6), 489-97. DOI: 10.1111/j.0894-0959.2004.17617.x.10.1111/j.0894-0959.2004.17617.x15660580Search in Google Scholar

10. Glorieux G, Neirynck N, Veys N, et al. (2012). Dialysis water and fluid purity: more than endotoxin. Nephrol Dial Transplant. 27(11), 4010-21. DOI: 10.1093/ndt/gfs306.10.1093/ndt/gfs30622844107Search in Google Scholar

11. Aziz MA, Majeed GH, Diab KS, et al. (2016). The association of oxidant-antioxidant status in patients with chronic renal failure. Ren Fail. 38(1), 20-6. DOI: 10.3109/0886022X.2015.1103654.10.3109/0886022X.2015.110365426524399Search in Google Scholar

12. Handelman GJ. (2007). Vitamin C deficiency in dialysis patients - are we perceiving the tip of an iceberg? Nephrol Dial Transplant. 22(2), 328-31. DOI: 10.1093/ndt/gfl534.10.1093/ndt/gfl53417107966Search in Google Scholar

13. Zalba G, Fortuño A, Diez J. (2006). Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant. 21(10), 2686-90. DOI: 10.1093/ndt/gfl398.10.1093/ndt/gfl39816861737Search in Google Scholar

14. Massy ZA. (2000). Importance of homocystein, lipoprotein (a) and non-classical cardiovascular risk factors (fibrinogen, and advanced glycation end-products) for atherogenesis in uraemic patients. Nephrol Dial Transplant. 15(Suppl 5), 81-91. DOI: 10.1093/ndt/15.suppl_5.81.10.1093/ndt/15.suppl_5.8111073279Search in Google Scholar

15. Culleton BF, Bostom AG. (2000). Hyperhomocysteinemia in chronic renal disease. In: Cardiovascular Disease in End-stage Renal Failure. Loscalzo J, London GM, (eds). The Oxford University Press, New York, 2000: 211-28.Search in Google Scholar

16. Kielstein JT, Frölich JC, Haller H, et al. (2001). ADMA (asymmetric dimethylarginine): an atherosclerotic disease mediating agent in patient with renal disease? Nephrol Dial Transplant. 16(9), 1742-5. DOI: 10.1093/ndt/16.9.1742.10.1093/ndt/16.9.174211522849Search in Google Scholar

17. Lacson E, Levin NW. (2004). C-Reactive Protein and End-Stage Renal Disease. Semin Dial. 17(6), 438-48. DOI: 10.1111/j.0894-0959.2004.17604.x.10.1111/j.0894-0959.2004.17604.x15660574Search in Google Scholar

18. Petrović D, Obrenović R, Poskurica M, i ost. (2007). Povezanost C-reaktivnog proteina sa ehokardiografskim parametrima hipertrofije i ishemijske bolesti srca u bolesnika koji se leče ponavljanim hemodijalizama. Med Pregl. LX (Suppl 2), 160-4.Search in Google Scholar

19. Akchurin OM, Kaskel F. (2015). Update on Inflammation in Chronic Kidney Disease. Blood Purif. 39(1), 84-92. DOI: 10.1159/000368940.10.1159/00036894025662331Search in Google Scholar

20. Koenig W. (2003). C-reactive protein and cardiovascular risk: an update on what is going on in cardiology. Nephrol Dial Transplant. 18(6), 1039-41. DOI: 10.1093/ndt/gfg103.10.1093/ndt/gfg10312748330Search in Google Scholar

21. Kanbay M, Perazella MA, Kasapoglu B, et al. (2010). Erythropoiesis Stimulatory Agent-Resistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purif. 29(1), 1-12. DOI: 10.1159/000245041.10.1159/00024504119816014Search in Google Scholar

22. Locatelli F, Canaud B, Eckardt KU, et al. (2003). Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 18(7), 1272-80. DOI: 10.1093/ndt/gfg074.10.1093/ndt/gfg07412808161Search in Google Scholar

23. Liakopoulos V, Roumeliotis S, Zarogiannis S, et al. (2019). Oxidative stress in hemodialysis: Causative mechanisms, clinical implications, and possible therapeutic interventions. Semin Dial. 32(1), 58-71. DOI: 10.1111/sdi.12745.10.1111/sdi.1274530288786Search in Google Scholar

24. Liakopoulos V, Roumeliotis S, Bozikas A, et al. (2019). Antioxidant Supplementation in Renal Replacement Therapy Patients: Is There Evidence? Oxidative Med Cell Long. 2019, Article ID 9109473, 23 pages. DOI: 10.1155/2019/9109473.10.1155/2019/9109473635061530774749Search in Google Scholar

25. Zhang KY, Zuo L. (2014). Vitamin C supplementation in patients on maintenance dialysis. W J Clin Urol. 3(3), 344-50. DOI: 10.5410/wjcu.v3.i3.344.10.5410/wjcu.v3.i3.344Search in Google Scholar

26. Coombes JS, Fassett RG. (2012). Antioxidant therapy in hemodialysis patients: a systematic review. Kidney Int. 81(3), 233-46. DOI: 10.1038/ki.2011.341.10.1038/ki.2011.34121975860Search in Google Scholar

27. Gokbel H, Atalay H, Okudan N, et al (2011). Coenzyme Q10 and its Relation with Oxidant and Antioxidant System Markers in Patients with End-Stage Renal Disease. Ren Fail. 33(7), 677-81. DOI: 10.3109/0886022X.2011.589941.10.3109/0886022X.2011.58994121787158Search in Google Scholar

28. Den Hoedt CH, Bots ML, Grooteman MPC, et al. (2014). Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 86(2), 423-32. DOI: 10.1038/ki.2014.9.10.1038/ki.2014.924552852Search in Google Scholar

29. Panichi V, Scatena A, Rosati A, et al. (2015). High-volume online hemodiafiltration improves erythropoiesis-stimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant. 30(4): 682-9. DOI: 10.1093/ndt/gfu345.10.1093/ndt/gfu34525385719Search in Google Scholar

30. Tarng DC, Huang TP, Liu TY, et al. (2000). Effect of vitamin E-bonded membrane on the 8-hydroxy 2,-deoxyguanosine level in leukocyte DNA of hemodialysis patients. Kidney Int. 58(2), 790-9. DOI: 10.1046/j.1523-1755.2000.00228.x.10.1046/j.1523-1755.2000.00228.x10916104Search in Google Scholar

31. Andrulli S, Di Fillipo S, Manzoni C, et al. (2010). Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. Nephron Clin Pract 115(1), 82-9. DOI: 10.1159/000294281.10.1159/00029428120215781Search in Google Scholar

32. Panagiotou A, Nalesso F, Zanella M, et al. Antioxidant Dialytic Approach with Vitamin E-Coated Membranes. In: Ronco C, Rosner MH. Eds. Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger, 2011; 171: 101-6.10.1159/000327204Search in Google Scholar

33. Panichi V, Rosati A, Paoletti S, et al. (2011). A vitamin E-coated polysulphone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial. Blood Purif. 32(1), 7-14. DOI: 10.1159/000321369.10.1159/00032136921242686Search in Google Scholar

34. Yang SK, Xiao L, Xu B, et al. (2014). Effects of vitamin E-coated dialyzer on oxidative stress and inflammation status in hemodialysis patients: a systematic review and meta-analysis. Ren Fail. 36(5), 722-31. DOI: 10.3109/0886022X.2014.890858.10.3109/0886022X.2014.89085824575826Search in Google Scholar

35. Yamadera S, Nakamura Y, Inagaki M, et al. (2017). Vitamin E-Coated Dialyzer Inhibits Oxidative Stress. Blood Purif. 44(4), 288-93. DOI: 10.1159/000478971.10.1159/00047897129065402Search in Google Scholar

36. D^’Arrigo G, Baggetta R, Tripepi G, et al. (2017). Effects of vitamin E-Coated versus Conventiional Membranes in Chronic Hemodialysis Patients: A Systemic Review and Meta-Analysis. Blood Purif. 43(1-3), 101-22. DOI: 10.1159/000453444.10.1159/00045344427960188Search in Google Scholar

37. Locatelli F, Andrulli S, Vigano SM, et al. (2017). Evaluation of the Impact of a New Synthetic Vitamin E-Bonded Membrane on the Hypo-Responsiveness to the Erythropoietin Therapy in Hemodialysis Patients: A Multicenter Study. Blood Purif. 43(4), 338-45. DOI: 10.1159/000453442.10.1159/00045344228249254Search in Google Scholar

38. Fishbane S, Singh AK, Cournoyer SH, et al. (2015). Ferric pyrophosphate citrate (Triferic^TM) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients. Nephrol Dial Transplant. 30(12), 2019-26. DOI: 10.1093/ndt/gfv277.10.1093/ndt/gfv277465603826175145Search in Google Scholar

39. Gupta A, Lin V, Guss C, et al. (2015). Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients. Kidney Int. 88(5), 1187-94. DOI: 10.1038/ki.2015.203.10.1038/ki.2015.203465358526154926Search in Google Scholar

40. Shah HH, Hazzan AD, Fishbane S. (2016). Ferric Pyro-phosphate Citrate: A Novel Iron Replacement Agent in Patients Undergoing Hemodialys. Semin Nephrol. 36(2), 124-9. DOI: 10.1016/j.semnephrol.2016.02.007.10.1016/j.semnephrol.2016.02.00727236134Search in Google Scholar

41. Fishbane S, Shah HH. (2017). Ferric pyrophosphate cit-rate as an iron replacement agent for patients receiving hemodialysis. Hemodialysis Int. 21(Suppl 1), 104-9. DOI: 10.1111/hdi.12554.10.1111/hdi.1255428371161Search in Google Scholar